Skip to main content

Intensity Therapeutics, Inc.

INTS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001567264

No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Intensity Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of INTS: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders2726−1
Shares1.98M2.96M+982.7K (+49.7%)
Value$606.6K$721.2K+$114.6K (+18.9%)

New holders (5)

Institutions that held Intensity Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to INTS in Q3 2025
InstitutionSharesValue% of portfolio
IHT Wealth Management, LLC47,483$11.5K0.00%
Citigroup Inc44,575$10.8K0.00%
Scientech Research LLC24,726$6.00K0.00%
Sassicaia Capital Advisers LLC20,000$4.85K0.00%
Two Sigma Securities, LLC18,448$4.48K0.00%

Sold out (6)

Institutions that held Intensity Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of INTS in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Jane Street Group, LLC44,897$13.8K
XTX Topco Ltd24,553$7.54K
HRT Financial LP24,904$7.00K
Boothbay Fund Management, LLC15,000$4.61K
Cubist Systematic Strategies, LLC11,673$3.58K
FMR LLC100$31